Home / News / India News / Article /
Bharat Biotech gets nod for Covid-19 intra-nasal vaccine phase-3 trials
Updated On: 28 January, 2022 04:16 PM IST | New Delhi | PTI
The trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as booster dose schedule
Listen to this article :
Photo for representational purpose. Pic/ istock
Bharat Biotech has received approval from the Drug Controller General of India to conduct phase-3 trials for its Covid-19 intra-nasal vaccine (BBV154), sources in the company said on Friday.
The trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as booster dose schedule, they said.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT